Analyst Price Target is $15.40
▲ +251.60% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Tenaya Therapeutics in the last 3 months. The average price target is $15.40, with a high forecast of $20.00 and a low forecast of $7.00. The average price target represents a 251.60% upside from the last price of $4.38.
Current Consensus is
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Tenaya Therapeutics. This Buy consensus rating has held steady for over two years.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More
